Jun 04, 2020
IRLAB's Phase IIb/III Study in Parkinson's disease to Target Good ON
May 26, 2020
Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting
Mar 27, 2020
Virtus Nutrition's Post Workout Ri-'k -v -re Formula Doesn't Pull Any Punches with Its All-Star Ingredients
Jan 30, 2020
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
Oct 28, 2019
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
Sep 25, 2019
Neuroscientist awarded $2.9M NIH grant to improve Parkinson's disease treatment
Sep 25, 2019
Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society
Sep 23, 2019
AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®
Sep 17, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
Sep 16, 2019
Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society
Aug 27, 2019
FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease
Jul 24, 2019
Parkinson's Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jul 22, 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Jun 25, 2019
Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders
Jun 19, 2019
Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders
May 05, 2019
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
May 02, 2019
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
Apr 30, 2019
Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting
Apr 30, 2019
AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
Apr 30, 2019
Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill(TM) Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients